Clinicopathological factors associated with tumor-infiltrating lymphocyte reactivity in breast cancer.

Heejae LeeYoung-Ae KimYoungho KimHye Seon ParkJeong-Han SeoHyun LeeGyungyub GongHee Jin Lee

Published in: Cancer immunology, immunotherapy : CII (2020)

TILs from approximately half the TNBC cases with NAC showed reactivity against autologous cancer cells. The proportion of PD-1+ T cells was higher in the reactive group. Adoptive TIL therapy combined with PD-1 inhibitors might be promising for TNBC patients with residual tumors after NAC.

Keyphrases

cell therapy
transcription factor
bone marrow
genome wide analysis
peripheral blood
stem cells
mesenchymal stem cells
platelet rich plasma